Clinical trial NCT05552833: Pulmonary Adaptive Responses to HIIT in COPD
Official title: Pulmonary Adaptive Responses to HIIT in COPD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: High intensity interval training (HIIT)
Lung growth
Diffusion capacity
Blood flow
Lung tissue mass
Oxygen extraction
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2022-09-23
Enrollment: 24
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 12 COPD will undergo the intervention in one arm and 12 healthy, age and BMI matched individuals will undergo the same intervention.
Primary purpose: BASIC_SCIENCE

Brief summary: Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. Regular exercise can improve quality of life in these patients, but the health care system lack the underlying mechanism of exercise-induced improvement in COPD and it is widely thought not to have any effect on lung function. The aim of the present study is to investigate to which extent lung tissue mass and rest-to-exercise diffusion capacity changes differ in COPD patients compared to the healthy state. In order to design prospective clinical trials on the putative impact of high-intensity interval training (HIIT) investigating these parameters, and a secondary aim is to assess the feasibility of such a study in terms of patient inclusion, adherence and methodology.

Detailed description: Patients with Chronic obstructive pulmonary disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. Regular exercise is considered the most effective non-pharmacological intervention for improving quality of life in these patients. However, its use is halted by the lack of understanding of the mechanism of exercise-induced improvement in COPD, and is widely thought not to have any effect on lung function in the clinical setting. Exercise is thus mainly considered a way to alleviate symptoms, primarily by improving skeletal muscle function, but without the potential to reverse the disease. Therefore, relatively short and low-intensity exercise interventions are typically prescribed and are often not pursued in patients with the greatest symptom burden.

The reasoning for not prescribing exercise more widely in COPD is based on two assumptions: 1) new tissue cannot be formed in the adult lung, and 2) no consistent exercise training-induced changes in lung function have previously been documented.

However, de novo tissue formation has repeatedly been demonstrated in the adult lung, both in animals and humans, primarily in response to prolonged hypoxia and pneumonectomy. It has recently been reported that interval-based training counteracts the progressive loss of lung tissue in animal models of experimental COPD. The most likely stimulus is the mechanical strain, and if any measurable changes are to be induced by training, a high-intensity interval training (HIIT) scheme is preferable to be initiated in pulmonary rehabilitation.

On this basis, this study aim to conduct a prospective randomised trial, in which the impact of HIIT on lung weight (assessed by CT), rest-to-exercise diffusion capacity, 3-dimensional distribution of pulmonary perfusion measured by single photon emission computed tomography (SPECT)-low dose CT are addressed. Indeed, the latter is an especially useful clinical tool for the pathophysiological classification of COPD patients, and rest-to-exercise SPECT has the potential as a diagnostic tool that 'pinpoints' the exact cause of dyspnoea in the individual COPD patient, but has not yet been validated for this purpose. While all the methods are established, there is a need for more information regarding COPD-associated changes in lung tissue mass ('lung weight') and rest-to-exercise pulmonary diffusion changes compared to the healthy state. An assessment of the feasibility of an extended HIIT-trial using these methods in COPD patients as well as estimates of the in-study changes in the resultant physiological estimates (for the purpose of sample size estimations) is warranted.

Eligibility criteria: Inclusion criteria -patients

* Men and women
* 45-80 years
* COPD (GOLD stage I to III)
* Forced expiratory volume in 1 sec (FEV1)/forced vital capacity ratio (FVC) \< 0.8, FEV1 \< 90% of predicted value
* Modified Medical Research Council score (mMRC 0 - 3)
* Resting arterial oxygenation \> 90%
* Do not fulfil the physical activity recommendations by the Danish Health Authority

Inclusion criteria - controls

* Men and women
* 45-80 years
* Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity
* Same sex, age (± 3 years) and BMI (± 10%)
* Do not fulfil the physical activity recommendations by the Danish Health Authority (19)
* BMI 18-35

Exclusion criteria - patients

* Symptoms of ischaemic heart disease
* Known heart failure
* Previous severe or current COVID-19
* Unable to complete or understand HIIT training
* Claudication
* Symptoms of disease within 2 weeks prior to the study
* Participation in pulmonary rehabilitation within 6 months
* Known malignant disease
* Pregnancy
* Unstable cardiac arrhythmic disease
* Renal or liver dysfunction

Exclusion criteria - controls

* COPD
* Asthma
* Known ischaemic heart disease
* Known heart failure
* Previous severe or current COVID-19
* Unable to complete or understand HIIT training
* Symptoms of disease within 2 weeks prior to the study
* Known malignant disease
* Claudication
* Pregnancy
* Unstable cardiac arrhythmic disease
* Renal or liver dysfunction

Primary outcomes:
measure: Lung tissue mass
timeFrame: CT-scans at baseline and at 12 week follow up.
measure: Rest-to-exercise diffusion capacity
timeFrame: DLNO/CO measured at baseline and at 12 week follow up.
Secondary outcomes:
measure: Rest-to-exercise pulmonary perfusion ratio change
timeFrame: At baseline and at 12 week follow up
measure: Rest-to-exercise leg blood flow change in COPD
timeFrame: At baseline and at 12 week follow up
Other outcomes:
measure: Rest-to-exercise cardiac output change
timeFrame: At baseline and at 12 week follow up
measure: VO2peak (and estimated VO2max)
timeFrame: At baseline and at 12 week follow up
measure: VO2 verification bout
timeFrame: At baseline and at 12 week follow up
measure: The maximal workload (knee extension)
timeFrame: At baseline and at 12 week follow up.
measure: Hand-grip strength
timeFrame: At baseline and at 12 week follow up.
measure: Body composition
timeFrame: At baseline and at 12 week follow up.
measure: Lung function: FEV1
timeFrame: At baseline and at 12 week follow up.
measure: Lung function: TLC
timeFrame: Measured during the 12 week intervention.
measure: Lung function: FVC
timeFrame: Measured during the 12 week intervention.
measure: Lung function: RV
timeFrame: Measured during the 12 week intervention.
measure: Lung function: VA
timeFrame: Measured during the 12 week intervention.
measure: Lung function: DLCOc
timeFrame: Measured during the 12 week intervention.
measure: 6-minute walking test
timeFrame: At baseline and at 12 week follow up.
measure: Chronic obstructive pulmonary disease Assessment Test (CAT-score)
timeFrame: At baseline and at 12 week follow up.
measure: Oxygen extraction in lower limb musculature during small mass exercise
timeFrame: At baseline and at 12 week follow up.
measure: Intima media thickness in the carotid artery
timeFrame: At baseline and at 12 week follow up.
measure: Exercise feasibility: exercise sessions attendance rate.
timeFrame: Measured during the 12 week intervention.
measure: Exercise feasibility: Relative dose intensity (RDI)
timeFrame: Measured during the 12 week intervention.
measure: Exercise feasibility: early exercise termination
timeFrame: Measured during the 12 week intervention.
measure: Withdrawal rate
timeFrame: Measured during the 12 week intervention.
measure: Exercise feasibility: Patient-reported symptomatic adverse events (paint, dizziness, nausea, fatigue, other)
timeFrame: Measured during the 12 week intervention.
measure: Glucose
timeFrame: At baseline and at 12 week follow up.
measure: IL-1
timeFrame: At baseline and at 12 week follow up.
measure: IL-1RA
timeFrame: At baseline and at 12 week follow up.
measure: TNF-alfa
timeFrame: At baseline and at 12 week follow up.
measure: IL-6
timeFrame: At baseline and at 12 week follow up.
measure: IL-10
timeFrame: At baseline and at 12 week follow up.
measure: Adiponectin
timeFrame: At baseline and at 12 week follow up.
measure: IL-15
timeFrame: At baseline and at 12 week follow up.
measure: HS-CRP
timeFrame: At baseline and at 12 week follow up.
measure: HDL
timeFrame: At baseline and at 12 week follow up.
measure: LDL
timeFrame: At baseline and at 12 week follow up.
measure: Insulin
timeFrame: At baseline and at 12 week follow up.
measure: Creatinine
timeFrame: At baseline and at 12 week follow up.
measure: Leptin
timeFrame: At baseline and at 12 week follow up.
measure: Carbamide
timeFrame: At baseline and at 12 week follow up.
measure: ALAT
timeFrame: At baseline and at 12 week follow up.
measure: Leucocytes
timeFrame: At baseline and at 12 week follow up.
Locations:
city: Copenhagen
country: Denmark
facility: Centre for Physical Activity Research (CFAS)
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
References: